99mTc-CNDG SPECT/CT in Brain Tumors
Recruiting now · Not applicable
Conditions studied: Intracranial Tumor
In brief
The goal of this clinical trial is to evaluate the value of 99mTc-CNDG for diagnosis of brain tumors by comparing it with 18F-FDG-PET. The main questions it aims to answer are: 1. What is the diagnostic consistency between 99mTc-CNDG and 18F-FDG? 2. What is the correlation between the SUVmax value of 99mTc-CNDG and tumor type? Participants will: Receive18F-FDG-PET and 99mTc-CNDG examination within 2 weeks before surgery. Obtain pathological diagnosis by surgery or biopsy as the gold standard.
Key facts
- Study ID
- NCT06362304
- Run by
- Peking Union Medical College Hospital
- People needed
- 30
- Starts
- 2024-04-20
- Expected to finish
- 2025-04-01
- Last updated by the study team
- 2024-11-25
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with clinical diagnosis of brain tumor;
- Be at least 18 years old;
- The final pathological results could be obtained by surgery or biopsy;
- Informed consent and the ability to be followed up;
- Those who did not meet the exclusion criteria.
You may not qualify if…
- Insulin-dependent diabetes mellitus or fasting blood glucose >7 mmol/L before 99mTc-CNDG injection;
- Severe liver or kidney disease (serum creatinine level >3.0mg/dL or any liver enzyme level ≥ 5 times the upper limit of normal);
- Severe hypersensitivity or hypersensitivity to radiocontrast agents;
- Claustrophobia (inability to undergo SPECT/CT or PET/CT scans);
- Patients receiving radiotherapy and chemotherapy;
- Being pregnant or breastfeeding.
Where it is running
- Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.